Collectively, these findings suggest that the amalgamation of cyclophosphamide and fludarabine chemotherapy, succeeded by the introduction of CD19 CAR-T cells after a five-day interval, potentially exerts its antineoplastic efficacy by perturbing the metabolic pathways within tumor cells. This evidence concerns the gene CD19 and neoplasm.